Search

everythinglearnresearchcommunity

for

Search:↓

A user received a custom topical treatment for hair loss from Rootsbyga, which includes minoxidil and possibly other ingredients to enhance its effectiveness. The initial test cost $120, and the monthly topical costs around $70, with concerns about long-term use of steroids like hydrocortisone.

The user has been using oral finasteride for 15 months and oral minoxidil for 6 months, and developed alopecia areata, for which a dermatologist prescribed calcipotriol/betamethasone. The treatment is helping, but the user is experiencing another shedding phase and is concerned about the effects of the steroid cream and the cause of hair loss.

An 18-year-old woman experiencing hair loss due to stress, possible PCOS, and low vitamin D is concerned about starting 5% minoxidil foam, prescribed by her doctor, due to potential facial hair growth. She is also using a topical steroid for scalp sensitivity and pain.

The user is using a comprehensive hair loss treatment including oral dutasteride, minoxidil (both oral and topical), topical finasteride, RU58841, ketoconazole shampoo, and a derma roller, while also using anabolic steroids. Opinions vary, with some users noting stability or slight improvement, while others suggest the treatment may not be effective due to anabolic use.

The conversation is about using Biolabshop's RU58841 product, which includes GHK-Cu and melatonin, to improve hair quality and combat hair loss. The user has previously used finasteride, minoxidil, and Anageninc’s RU58841 with success and seeks feedback on the new product, especially from those on anabolic steroids or hormone treatments.

Experimenting with trestolone as a treatment for hair loss in an attempt to avoid DHT-related treatments such as finasteride and dutasteride, and discussing the potential effects of its receptor selectivity on the androgen receptors in the scalp.

Female considering adding topical anti-androgen, seeks advice on RU58841 or pyrilutamid's binding affinity compared to spironolactone.

The user is trying a new hair loss treatment combining 1.25 mg oral minoxidil with a daily topical solution containing hydrocortisone, tretinoin, 8% minoxidil, and 0.025% finasteride. They aim to maintain their current hair before considering a hair transplant in Istanbul.

The user is considering RU58841 and has been using dutasteride since age 17. They are seeking affordable SARD options, mentioning ASC-J9, GT20029, and AH001.

The user has DUPA and suspects autoimmune activity as a cause. They have tried various treatments including finasteride, minoxidil, dutasteride, pyrilutamide, estrogel, hydrocortisone, and clobetasol, and are now seeking a long-term immunosuppressant.

Hair loss treatments, including Alfatradiol, Minoxidil, Finasteride, and RU58841. It discusses the efficacy of these treatments for hair growth and regrowth.

The conversation is about hair loss and the conclusion is that genetics play a significant role in hair loss, and lifestyle choices or being a well-adjusted person do not prevent male pattern baldness.

Clascoterone (Breezula) showed positive results for treating hair loss without affecting cortisol levels. Opinions vary, with some users optimistic about its potential and others critical of its effectiveness compared to existing treatments like finasteride.

Orient Bio is developing a PLGA formulated version of Cyclosporine A to stimulate hair growth without its immunosuppressant effects. Users discuss various treatments like Clascoterone, PP405, minoxidil, and tacrolimus, expressing hope for new developments and sharing personal experiences with these treatments.

Managing blood pressure can help with hair loss, as seen with the use of medications like Cialis and oral minoxidil, which improved hairline and blood pressure. Lifestyle changes, such as reducing stimulant use and adjusting testosterone replacement therapy (TRT) doses, also play a role in addressing hair loss and overall health.

A user was prescribed betamethasone dipropionate spray for a receding hairline, which caused skin peeling and depigmentation. They stopped using it and are considering alternatives like BPC-157/TB-500 for healing.

A user is seeking advice on the efficacy and side effects of homemade topical solutions for hair loss, specifically bicalutamide, estradiol, cyproterone acetate, and spironolactone, as they cannot access RU58841 or pyrilutamide.

The conversation discusses using estradiol mesotherapy to replicate hormone replacement therapy results while minimizing systemic exposure. It also covers the use of Spironolactone cream, which reportedly has no systemic side effects, and the potential risks of using bicalutamide and Spironolactone in men.

Spironolactone, finasteride, and dutasteride are discussed for hair maintenance, with concerns about testosterone and side effects like gynecomastia. Spironolactone is noted for use in both bodybuilding and hormone therapy, with low doses considered for minimizing side effects.

Female with PCOS experiences receding and thinning hair, wants dutasteride instead of spironolactone. Discusses desire to reduce DHT without losing libido.

The user is experiencing diffuse thinning and inflammation despite using 2.5mg dutasteride daily, ciclopirox, and ketoconazole shampoos. They are considering treatments like hydroxychloroquine and JAK inhibitors due to suspected scarring alopecia and have faced challenges in obtaining a scalp biopsy.

The conversation discusses the safety and use of ketoconazole shampoo for hair loss, with mentions of zinc pyrithione and selenium sulfide. Users debate the safety of these ingredients, particularly zinc pyrithione, and share opinions on regulatory differences between Europe and the US.

A user experienced significant swelling after a hair and beard transplant, possibly due to an allergic reaction or improper post-surgery care. Despite dissatisfaction with the clinic's handling of grafts and customer service, the user appreciates the clinic's skill in achieving natural hairline density.

The conversation discusses alternative and unorthodox hair loss treatments, including RU58841, nandrolone, and dianabol, as well as theoretical approaches involving high doses of estrogen and selective estrogen receptor modulators. These methods are considered extreme and potentially harmful but are explored for those unable to tolerate traditional 5-alpha reductase inhibitors.

A user with scalp psoriasis and hair loss is hesitant to use topical minoxidil and finasteride due to concerns about psoriasis and potential side effects. They are considering alternatives like pumpkin seed and saw palmetto.

FCE 28260 (PNU 156765), an under-explored 5α-reductase inhibitor, showcases promising results in research by Giudici et al., outperforming well-known treatments like Finasteride in reducing the conversion of testosterone to DHT. Its superior efficacy, demonstrated through lower IC50 values in both natural and human recombinant enzyme studies, suggests it could offer more effective management of DHT-related conditions. Additionally, its lower molecular weight hints at better potential for topical application, potentially offering advantages in treating conditions such as androgenic alopecia. Despite its potential, it has not advanced in development, possibly due to financial limitations, leaving its therapeutic prospects and side effect profile largely unexplored.

RU58841 is a strong non-steroidal antiandrogen for hair loss but may cause cardiovascular issues in some users. Alternatives like Pyrilutamide and Breezula are suggested due to better safety profiles and lower systemic risks.

The conversation discusses topical androgen receptor blockers for hair loss, mentioning Clascoterone, Pyrilutamide, GT20029, and RU58841. Ketoconazole's effectiveness and application methods are also debated.

RU58841, an anti-androgenic compound, showed early promise for treating alopecia but faced challenges after its patent in 1997. Despite advancing to Phase II trials, safety concerns and financial struggles led Aventis to abandon its development. Proskelia, which later merged into ProStrakan, couldn't prioritize the drug, leading to its eventual stagnation and failure to reach the market.

A 30-year-old female with PCOS and male pattern baldness is frustrated with her endocrinologist's recommendation of only Spironolactone and minoxidil, feeling that dutasteride, finasteride, and progesterone would be more effective. Other users suggest various online sources for treatments, warn against self-medicating due to potential risks, and recommend seeking a specialized endocrinologist or considering additional treatments like Inositol, Berberine, and dermaneedling.